Conditioning with targeted busulfan for autologous peripheral blood stem cells transplantation for acute myelogenous leukemia in an XYY male.
We report herein a 19-year-old Japanese male with XYY syndrome who developed acute myelogenous leukemia. During three courses of cytotoxic chemotherapy, he suffered repeated hepatic and renal insufficiencies, possibly related to latent dysfunction from the XYY syndrome. The patient was treated with granulocyte colony-stimulating factor combined with etoposide, cytarabine, and busulfan (the latter adjusted to a targeting dose) followed by autologous peripheral blood stem cell transplantation. He had no severe regimen-related toxicities and is now free of leukemia.
Sada
Eriko
E
Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Henzan
Hideho
H
Ohtani
Ryoko
R
Takase
Ken
K
Miyamoto
Toshihiro
T
Fukuda
Takahiro
T
Nagafuji
Koji
K
Yamauchi
Keita
K
Takamatsu
Yasushi
Y
Inaba
Shoichi
S
Harada
Mine
M
D000328:Adult; D002066:Busulfan / Q000008:administration & dosage* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000601:surgery*; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014997:XYY Karyotype
D007166:Immunosuppressive Agents; D002066:Busulfan